Skip to main content
Premium Trial:

Request an Annual Quote

Structural Bioinformatics Licenses Database to De Novo

NEW YORK, Nov 21 – Structural Bioinformatics of San Diego said Tuesday it had licensed its SBdBase database of 3-dimensional protein structures to De Novo Pharmaceuticals.

Under the terms of the deal, De Novo will have access to multiple therapeutic target classes, Structural Bioinformatics said in a statement.

Financial terms were not disclosed.

" The combination of SBI's proprietary protein structures with De Novo's powerful proprietary drug design algorithms extends our design platform from experimentally determined protein structures to the broader world of sequence-based information,” David Bailey, De Novo's CEO, said.

“The agreement with SBI will allow De Novo to expand its drug design partnerships with early-stage genomics targets," he said. 

De Novo of Cambridge, UK, uses proprietary computational software for drug design to create lead molecules as candidates for drug development.

De Novo has collaborated with British Biotechnology and Aventis Pharma.

The Scan

Not Immediately Told

The US National Institutes of Health tells lawmakers that one of its grantees did not immediately report that it had developed a more infectious coronavirus, Science says.

Seems Effective in Kids

The Associated Press reports that the Pfizer-BioNTech SARS-CoV-2 vaccine for children appears to be highly effective at preventing symptomatic disease.

Intelligence Warning on Bioeconomy Threats

US intelligence warns over China's focus on technologies and data related to the bioeconomy, the New York Times reports.

PLOS Papers on Campylobacteriosis Sources, Inherited Retinal Dystrophies, Liver Cancer Prognosis

In PLOS this week: approach to uncover source of Campylobacteriosis, genetic risk factors for inherited retinal dystrophies, and more.